Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23067998 | 0.82 | — | — | |
| SCHEMBL2336421 | 0.82 | ACE2 (0.40) | CA12CA1CA2CA9ACE2 | |
| SCHEMBL21169723 | 0.78 | KDM1A (0.41) | SMN1; SMN2KDM1ACA12CA1CA2 | |
| SCHEMBL1958727 | 0.76 | KDM1A (0.40) | SMN1; SMN2KDM1ACA12CA1CA2 | |
| SCHEMBL2744386 | 0.76 | KDM1A (0.40) | SMN1; SMN2KDM1ACA12CA1CA2 | |
| SCHEMBL6505659 | 0.76 | ALDH1A1 (0.41) | SMN1; SMN2KDM1ACA12CA1CA2 | |
| SCHEMBL7004174 | 0.74 | KDM1A (0.39) | SMN1; SMN2KDM1ACA12CA1CA2 | |
| Hydrazine SCHEMBL8557171 | 0.74 | HTT (0.46) | SMN1; SMN2KEAP1KDM1ACA12CA1 | |
| SCHEMBL28793411 | 0.73 | ACE2 (0.34) | CA12CA9ACE2 | |
| SCHEMBL9126435 | 0.73 | KDM1A (0.38) | SMN1; SMN2KEAP1KDM1ACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354172-B2 | Process for encapsulating a water insoluble active | AKZO NOBEL N.V. (NL) | 2013-01-15 | — | — | US | claimed |
| CN-1678321-A | Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds | RIGEL PHARMACEUTICALS INC (US) | 2005-10-05 | — | — | CN | disclosed |
| US-5373095-A | Steroid compounds | THE UPJOHN COMPANY (US) | 1994-12-13 | — | — | US | disclosed |
| US-5334712-A | Estrane or androstane pyridinyl alkyl or alkylphenyl amine steroids for antidiabetes and obesity | THE UPJOHN COMPANY (US) | 1994-08-02 | — | — | US | disclosed |
| US-5274089-A | A estra-1,3,5(10)-triene derivative | THE UPJOHN COMPANY (US) | 1993-12-28 | — | — | US | disclosed |
| US-5196542-A | Phospholipase A2 inhibitors | THE UPJOHN COMPANY (US) | 1993-03-23 | — | — | US | disclosed |
| US-5187299-A | Phospholipase inhibitors; treating diabetes, obesity | THE UPJOHN COMPANY (US) | 1993-02-16 | — | — | US | disclosed |
| US-5145874-A | Phospholipase inhibitor, hypoglycemic agent, antidiabetic, obesity | THE UPJOHN COMPANY (US) | 1992-09-08 | — | — | US | disclosed |
| US-4917826-A | TREATING DIABETES AND OBESITY | THE UPJOHN COMPANY (US) | 1990-04-17 | — | — | US | disclosed |
| US-4764525-A | N-1H-tetrazol-5-ylbenzamides having use as antiallergy and antiinflammatory agents | WARNER-LAMBERT COMPANY (US) | 1988-08-16 | — | — | US | disclosed |